Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5475-5479

  Bosso, John A ^a,b,c   Nappi, Jean ^a,b   Rudisill, Celeste ^a,b   Wellein, Marlea ^d   Bookstaver, P Brandon ^a,b   Swindler, Jenna ^e   Mauldin, Patrick D ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of South Carolina   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MUSC Medical Center   (United States)

^e McLeod Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CONTRAST MEDIUM; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TACROLIMUS; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; AGE; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; GENDER; HEART DISEASE; HEART INFARCTION; HEMIPLEGIA; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NEPHROTOXICITY; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; RISK ASSESSMENT; SOLID TUMOR; STEADY STATE; TREATMENT DURATION; ULCER; WOUND INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CREATININE; CROSS INFECTION; FEMALE; HOSPITALS; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SOUTH CAROLINA; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 81555200425     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00168-11     Document Type: Article

References (36)

1. Abramson, M. A., and D. J. Sexton. 1999. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus: at what costs? Infect. Control Hosp. Epidemiol. 20:408-411.
2. Centers for Disease Control and Prevention. Accessed 9 December 2010. Active bacterial core surveillance (ABCs) report, emerging infections program network, methicillin-resistant Staphylococcus aureus, 2008. http://www .cdc.gov/abcs/reports-findings/survreports/mrsa08.html.
3. Charles, P. G. P., P. B. Ward, P. D. R. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451. (Pubitemid 38200128)
4. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 40:373-383. (Pubitemid 17055592)
5. Cosgrove, S. E., et al. 2003. Comparison of mortality associated with methicillin- resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36:53-59. (Pubitemid 36099097)
6. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501. (Pubitemid 38029149)
7. Engemann, J. J., et al. 2003. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36:592-598. (Pubitemid 36259564)
8. Fischer, M. J., B. B. Brimhall, D. C. Lezotte, J. E. Glazner, and C. R. Parikh. 2005. Uncomplicated acute renal failure and hospital resource utilization: a retrospective multicenter analysis. Am. J. Kidney Dis. 46:1049-1057. (Pubitemid 41690230)
9. Forouzesh, A., P. A. Moise, and G. Sakoulas. 2009. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob. Agents Chemother. 53:483-486.
10. Haque, N. Z., et al. 2010. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 138:1356-1362.
11. Harbarth, S., O. Rutschmann, P. Sudre, and D. Pittet. 1998. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch. Int. Med. 158:182-189. (Pubitemid 28049512)
12. Hidayat, L. K., D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer. 2006. High dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch. Intern. Med. 166:2138-2144. (Pubitemid 44631403)
13. Hidron, A. I., et al. 2008. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
14. Jeffres, M. N., W. Isakow, J. A. Doherty, S. T. Micek, and M. H. Kollef. 2007. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther. 29:1107-1115. (Pubitemid 47208584)
15. Kallen, A. J., et al. 2010. Health-care associated invasive MRSA infections, 2005-2008. JAMA 304:641-648.
16. Kaye, K. S., et al. 2008. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin. Infect. Dis. 46:1568-1577. (Pubitemid 351706738)
17. Klevens, R. M., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
18. Kullar, R., S. L. Davis, D. P. Levine, and M. J. Rybak. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
19. Lodise, T. P., et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
20. Lodise, T. P., B. M. Lomaestro, J. Graves, K. A. Rodvold, and G. L. Drusano. 2008. Larger vancomycin doses (≥4 grams/day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52: 1330-1336. (Pubitemid 351521995)
21. Lodise, T. P., et al. 2008. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteremia. J. Antimicrob. Chemother. 62:1138-1141.
22. Lodise, T. P., N. Patel, B. M. Lomaestro, K. A. Rodvold, and G. L. Drusano. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
23. Maclayton, D. O., K. J. Suda, K. A. Coval, C. B. York, and K. W. Garey. 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28:1208-1216. (Pubitemid 44374748)
24. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942. (Pubitemid 39447034)
25. Noskin, G. A., et al. 2005. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 nationwide inpatient sample database. Arch. Intern. Med. 165:1756-1761. (Pubitemid 41138964)
26. Patel, P., et al. 2011. Vancomycin: we can't get there from here. Clin. Infect. Dis. 52:969-974.
27. Pritchard, L., et al. 2010. Increasing vancomycin serum trough concentration and incidence of nephrotoxicity. Am. J. Med. 123:1143-1149.
28. Rhee, K. Y., D. F. Gardiner, M. Charles. 2005. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin. Infect. Dis. 40:1705-1706. (Pubitemid 40720831)
29. Rybak, M. J. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42:S35-S39. (Pubitemid 41832063)
30. Rybak, M., et al. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health-Syst. Pharm. 66:82-98.
31. Sader, H. S., P. R. Rhomberg, and R. N. Jones. 2009. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:3162-3165.
32. Sakoulas, G., et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. (Pubitemid 38747480)
33. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005. J. Antimicrob. Chemother. 60:788-794. (Pubitemid 47434257)
34. Styers, D., D. J. Sheehand, P. Hogan, and D. F. Sahm. 2006. Laboratorybased surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5:2.
35. Wang, G., et al. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886. (Pubitemid 44737223)
36. Wong-Beringer, A., J. Joo, E. Tse, and P. Beringer. 2011. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int. J. Antimicrob. Agents. 37:95-101.